Results 71 to 80 of about 461 (138)

Therapeutic Sequencing in Obstructive Hypertrophic Cardiomyopathy: Seeing the Forest Through the Trees. [PDF]

JACC Heart Fail
Reza N.
europepmc   +1 more source

A sharing session by a visiting research fellow of the Oxford Centre for clinical magnetic resonance research (OCMR) / Shubashini Gnanasan [PDF]

Dr. Shubashini Gnanasan, a senior lecturer from the Faculty of Pharmacy, UiTM presented her research experience of being part of a clinical trial team at the University of Oxford. She has been conducting ethnography to understand the facilitators and the
Gnanasan, Shubashini
core  

Aficamten in Obstructive Hypertrophic Cardiomyopathy

JACC
Andrew Wang, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Michael E. Nassif, Maria Luisa Peña-Peña, Roberto Barriales-Villa, Ozlem Bilen, Melissa Burroughs, Brian L. Claggett, Juan Pablo Costabel, Edileide de Barros Correia, Anne Dybro, Perry Elliott, Sheila M. Hegde, Ian J. Kulac, Neal K. Lakdawala, Gregory D. Lewis, Amy Mann, Ajith Nair, Steen H. Poulsen, Patricia Reant, P. Christian Schulze, Scott D. Solomon, Regina Sohn, Indrias Berhane, Stephen B. Heitner, Daniel L. Jacoby, Stuart Kupfer, Fady I. Malik, Amy Wohltman, Michael A. Fifer, Martin S. Maron   +32 more
openaire   +1 more source

Incidence of Ventricular Arrhythmias and Sudden Cardiac Death with Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials. [PDF]

J Pers Med
Katic J, Bulum T, Borovac JA.
europepmc   +1 more source

Újszerű terápiás lehetőségek hipertrófiás obstruktív kardiomiopátiában: Miozin inhibitorok

A hipertrófiás obstruktív kardiomiopátia (HOCM) napjaink egyik leggyakoribb genetikai eredetű szívbetegsége, mely jelentős életminőség-romlást okozhat, súlyos esetben pedig a hirtelen szívhalál kockázatának növekedésével jár.
Singlár, Fanni
core  

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: Clinical Advances and Therapeutic Prospects. [PDF]

Drug Des Devel Ther
Hou L, Lin B, Ji X, Huang A.
europepmc   +1 more source

Pharmacologic therapies for hypertrophic cardiomyopathy: The past, the present, and the future. [PDF]

JRSM Cardiovasc Dis
Halațiu VB, Cozac DA, Scridon A.
europepmc   +1 more source

Myosin Modulators Mavacamten and Aficamten Inhibit Cardiac Contractility Through Different Mechanisms

Journal of Molecular and Cellular Cardiology Plus
Saffie Mohran, Kristina Kooiker, Galina Flint, Max Mahoney-Schaefer, Weikang Ma, Timothy McMillen, Thomas Irving, Michael Regnier, Farid Moussavi-Harami   +8 more
doaj   +1 more source

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. [PDF]

Int J Mol Sci
Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, Yano T, Inomata T.   +7 more
europepmc   +1 more source

Novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl) -2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide

: The present invention relates to a novel process for the preparation of (R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazole-4-carboxamide, which is referred to as Aficamten and represented by the following structural
, Anonymous
core